BriaCell Therapeutics Corp Company Review & Valuation
About BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer.
Its lead product candidate is Bria-IMT that is in Phase I/IIA clinical trial for the patients with advanced breast cancer.
The trial was being conducted with the co-development of BriaDX, a companion diagnostic test.
The company is also conducting a combination study of Bria-IMT with pembrolizumab or ipilimumab for patients with advanced breast cancer.
In addition, it is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced stage breast cancer.
Further, the company has preclinical small molecule program that consists of various selective protein kinase C delta inhibitors for cancer and fibrotic diseases.
BriaCell Therapeutics Corp.
is headquartered in West Vancouver, Canada.